Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

被引：1

作者：

Chan, S. L. ^{[1
]}

Kudo, M. ^{[2
]}

Sangro, B. ^{[3
,4
,5
]}

Kelley, R. K. ^{[6
]}

Furuse, J. ^{[7
]}

Park, J-W. ^{[8
]}

Sunpaweravong, P. ^{[9
]}

Fasolo, A. ^{[10
]}

Yau, T. ^{[11
]}

Kawaoka, T. ^{[12
]}

Cheng, A-L. ^{[13
,14
]}

Azevedo, S. ^{[15
]}

Reig Monzon, M. E. ^{[16
]}

Assenat, E. ^{[17
]}

Yarchoan, M. ^{[18
]}

He, A. R. ^{[19
]}

Makowsky, M. ^{[20
]}

Gupta, C. ^{[21
]}

Negro, A. ^{[20
]}

Abou-Alfa, G. K. ^{[22
,23
]}

机构：

[1] Chinese Univ Hong Kong, Sir Yue Kong Pao Ctr Canc, Dept Clin Oncol, State Key Lab Translat Oncol, Hong Kong, Peoples R China

[2] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan

[3] Clin Univ Navarra, Liver Unit, Pamplona, Spain

[4] Clin Univ Navarra, HPB Oncol Area, Pamplona, Spain

[5] CIBEREHD, Pamplona, Spain

[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[7] Kanagawa Canc Ctr, Dept Gastroentel, Yokohama, Tokyo, Japan

[8] Natl Canc Ctr, Ctr Liver & Pancreatobiliary Canc, Dept Gastroenterol & Hepatol, Goyang, South Korea

[9] Prince Songkla Univ Hosp, Dept Internal Med, Songkhla, Thailand

[10] Fdn Michelangelo, Dept Med Oncol, Milan, Italy

[11] Queen Mary Hosp, Dept Med, Pok Fu Lam, Hong Kong, Peoples R China

[12] Hiroshima Univ, Dept Gastroenterol & Metab, Hiroshima, Japan

[13] Natl Taiwan Univ, Ctr Canc, Dept Oncol, Taipei, Taiwan

[14] Natl Taiwan Univ Hosp, Taipei, Taiwan

[15] UPCO Hosp Clin Porto Alegre, Dept Internal Med, Porto Alegre, RS, Brazil

[16] Univ Barcelona, Hosp Clin Barcelona, Barcelona Clin Liver Canc BCLC, Liver Unit,IDIBAPS,CIBEREHD, Barcelona, Spain

[17] Montpellier Univ, St Eloi Hosp, Dept Med Oncol, Montpellier, France

[18] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD USA

[19] Georgetown Univ, Lombardi Comprehens Canc Ctr, Div Hematol & Oncol, Washington, DC USA

[20] AstraZeneca, Oncol R&D, Late Stage Dev, Gaithersburg, MD USA

[21] AstraZeneca, Stat, Wilmington, DE USA

[22] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[23] Cornell Univ, Weill Med Coll, New York, NY 10021 USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.10.103

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

67O

引用

页码：S1456 / S1456

页数：1

共 50 条

[1] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Gupta, C.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
[2] Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Monzon, M. E. Reig
Tam, V. C.
Sangro, B.
Archambeaud, I.
Kelley, R. K.
Chan, S. L.
Kudo, M.
Masi, G.
Paskow, M. J.
Makowsky, M.
Gupta, C.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2024, 35 : S75 - S76
[3] Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
Rimassa, L.
Dayyani, F.
Kelley, R. K.
Sangro, B.
Chan, S. L.
Mccoy, C. L.
Paskow, M. J.
Makowsky, M.
Gupta, C.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2024, 35 : S77 - S78
[4] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, L. S.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S869 - S870
[5] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1465 - S1466
[6] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
Lau, George
Cheng, Ann-Lii
Sangro, Bruno
Kudo, Masatoshi
Kelley, Robin Kate
Tak, Won Young
Gasbarrini, Antonio
Reig, Maria
Lim, Ho Yeong
Tougeron, David
De Toni, Enrico N.
Tam, Vincent C.
Mody, Kabir
Gong, Jun
Mccoy, Carrie L.
Gupta, Charu
Makowsky, Mallory
Negro, Alejandra
Abou-Alfa, Ghassan K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
Sangro, Bruno
Galle, Peter R.
Kelley, Robin Kate
Charoentum, Chaiyut
De Toni, Enrico N.
Ostapenko, Yurii
Heo, Jeong
Cheng, Ann-Lii
Woods, Andrea Wilson
Gupta, Charu
Abraham, Jayne
Mccoy, Carrie L.
Patel, Nikunj
Negro, Alejandra
Vogel, Arndt
Abou-Alfa, Ghassan K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23)
[8] Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC)
Galle, P. R.
Crysler, O., V
Yarchoan, M.
Furuse, J.
Sukeepaisarnjaroen, W.
Thinh, N. T.
Masi, G.
Lim, H. Y.
Varela, M.
Gupta, C.
Makowsky, M.
Negro, A.
Abou-Alfa, G. K.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 129 - 129
[9] Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
Crysler, Oxana V.
Yarchoan, Mark
Furuse, Junji
Galle, Peter R.
Sukeepaisarnjaroen, Wattana
Nguyen Tien Thinh
Masi, Gianluca
Lim, Ho Yeong
Varela, Maria
Gupta, Charu
Makowsky, Mallory
Negro, Alejandra
Abou-Alfa, Ghassan K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 551 - 551
[10] Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Sangro, B.
Kelley, R. K.
Lau, G.
Kudo, M.
Sukeepaisarnjaroen, W.
De Toni, E. N.
Furuse, J.
Kang, Y-K.
Galle, P. R.
Rimassa, L.
Heurgue, A.
Tam, V. C.
Dao, T. V.
Thungappa, S. Chiradoni
Breder, V.
Ostapenko, Y. V.
Reig Monzon, M. E.
Gupta, C.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S1530 - S1531

← 1 2 3 4 5 →